Vice President of Regulatory Affairs
Bruce Krattenmaker has deep experience leading global regulatory and clinical affairs for start-up and large medical device companies. Krattenmaker has a legacy of new and creative approaches to gaining swift approvals for medical device technology. Prior to joining Alucent Biomedical, Krattenmaker was Vice President of global regulatory affairs for Allergan where he led worldwide regulatory affairs for the company’s entire $3 billion medical device franchise. Previously at Johnson & Johnson, Krattenmaker was Vice President of regulatory affairs, quality assurance and clinical programs and a management board member, where he led the internal and external development of Closure Medical Corporation, a biomaterials business, culminating in its acquisition by Johnson & Johnson. Before this, Krattenmaker was Vice President of ev3 (now Medtronic), where he was a key member of the mergers & acquisitions team for numerous critical acquisitions and integrations. Krattenmaker also held executive positions with various organizations including Biocompatibles Cardiovascular, Inc.; Valigen, Inc.; Boston Scientific Corporation; and C.R. Bard, Inc. Krattenmaker received a Bachelor of Science in Biology and Master of Science in microbiology and biochemistry from Northern Illinois University.